AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Jan, 23, 2023
“Statistically significant improvements in lung fu... See more
Dec, 3, 2022
Anavex said that the candidate's safety profil... See more
RSLS
ReShape Lifesciences Inc.
-48.86%
$5.91 - $3.02
Feb 8th 2023 - Mar 22nd 2023
Jan, 23, 2023
“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023” Oh, 48 weeks! !
Dec, 3, 2022
Anavex said that the candidate's safety profile also appeared to be relatively good.
Nov, 30, 2022
Anavex also better in ADAS-Cog14, and far superior safety profile.
Nov, 18, 2022
>> no clinically significant treatment-related adverse events and no serious adverse events = PERFECT SAFETY PROFILE !!
Nov, 14, 2022
$AVXL safety profile = excellent !!
Oct, 30, 2022
with Blarcamesine's outstanding safety profile this will become the #1 off label prescribed drug in the world.
Oct, 4, 2022
$AVXL for Hans, yes $avxl is great and will get approved when it’s high dose arm absolutely crushes the current SOC with a flawless safety profile.
No reviews available.